Browse articles from the EyeWorld December 2022 issue. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Still a relatively new technology that is being incorporated into more devices, epithelial mapping use continues to become more widespread among refractive surgeons. From an availability standpoint, Dan Reinstein, MD, who pioneered mapping the epithelium, said “every OCT company is developing or has developed this functionality into their machines.”
For the last decade, interferon alpha-2b was the preferred pharmacologic therapy for ocular surface squamous neoplasia (OSSN) in the U.S. However, with the pandemic, the makers of interferon transitioned its use for treatment of COVID-19 patients instead. This article covers other OSSN treatment options.
While glaucoma specialists are likely familiar with MicroPulse Laser Therapy (Iridex) as a non-incisional, non-pharmaceutical glaucoma therapy, two physicians called it an “ace up your sleeve” and one that can be adopted by any surgeon who treats glaucoma patients.
The December episode of the ASCRS YES Connect Webinar series covers research within a private practice setting. While it might seem that practicing in an academic setting dovetails well with research, Morgan Micheletti, MD, said one shouldn’t discount the amount of research that can be done in private practice.
Medical students and physicians today face a career where the effects of climate change on human health must be factored into the patient care model, according to medical student Margaret Tharp. In the article, she offered advice for medical students and physicians seeking climate action.
The use of NSAIDs in the context of cataract surgery remains a hot topic among surgeons. EyeWorld spoke with two ophthalmologists to hear their current perspectives on NSAID use in cataract surgery.
The EVO Visian ICL (STAAR Surgical) was recently approved for the treatment of myopia and astigmatism, with updates to the previous ICL technology. Several physicians discussed the technology with EyeWorld: what’s new, how they’re using the product, and results they’ve seen so far.
When treating endothelial dysfunction, surgeons have several options. The current standard of care is endothelial keratoplasty, DSAEK and DMEK. One new therapy that has been getting a lot of attention is corneal endothelial cell therapy, and there has been significant progress in the last 18 months.
Two physicians shared their reasons for and experiences with combining MIGS procedures.
January is an important month for businesses, and arguably the most important month for achieving new year resolutions. Utilize time off during the holidays to analyze branding, employees, and operations. Executing the first month will set the stage for the rest of 2023, according to this article.